Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Combined Synopsis/Solicitation opportunity from Department Of Defense was posted on October 18, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

INTERCEPT Blood System Platelet Processing and ILLUMINATOR Service Maintenance

Awarded
HT941025N0005Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413
New
DIBBS
CULTURE MEDIUM, THAYER-
Solicitation # SPE2DS-27-T-1066
Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.
MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

about 21 hours ago

DEADLINE

in 5 days
NAICS: 325413
New
Federal
6550--Optilite analyzer reagents
Solicitation # 36C26227Q0052
The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.
262-NETWORK Contract Office 22 (36C262)

POSTED

2 days ago

DEADLINE

in 6 days
NAICS: 325413
New
Federal
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Solicitation # HT942627QE003
The Defense Health Agency is soliciting quotations to establish a Blanket Purchase Agreement (BPA) for the recurring resupply of consumable products for three Terumo Trima Accel Blood Collection Systems used by the USAISR Combat Casualty Care Research Team 1 in Texas. To maintain FDA approval and satisfy research protocols, the contractor must provide original manufacturer-supplied consumables, including Teruflex 500ml collection bags, Trima Platelet Kits, Isoplate Solution (PAS-F), TSCD Wafers, ACD-A Solution, and 150 mL couplers. This procurement is a 100 percent set-aside for Service-Disabled Veteran-Owned Small Businesses under NAICS 325413. The resulting BPA will have a 60-month ordering period with a total ceiling of 35 million dollars, though some documentation notes a lower limit of 350,000 dollars. Individual call orders are capped at 50,000 dollars, while Government Purchase Card orders are limited to 15,000 dollars. Awards will be made on a Lowest Price Technically Acceptable basis, with technical capability rated as pass or fail. All payment requests and receiving reports must be processed electronically through the Wide Area WorkFlow system. Quotations are due by November 6, 2026, and must be submitted in two separate volumes covering technical capability and pricing.
Army Medical Resources Acq Activity

POSTED

6 days ago

DEADLINE

in 8 days
NAICS: 325413
Federal
6550--VISN Cepheid GeneXpert Testing Supplies Base Plus 3 Op Yr RFQ
Solicitation # 36C24527Q0042
The Department of Veterans Affairs, specifically the VA North Atlantic Health Network (HSA 1.3), is soliciting a firm-fixed-price, Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Cepheid GeneXpert testing supplies. This requirement covers the procurement of FDA-approved reagents, consumables, and service for PCR analyzers to detect various pathogens, including CoV-2, Influenza, RSV, MRSA, and Mycobacterium Tuberculosis. The contract is structured with a base period ending October 31, 2027, and three subsequent one-year option periods extending through October 31, 2030. Deliveries will be made to multiple VA Medical Centers across Maryland, West Virginia, and Washington DC. This acquisition is set aside for HUBZone small businesses. Award will be determined using the Lowest Price Technically Acceptable (LPTA) method, evaluating technical acceptability, delivery performance, past performance, and price, with additional credit given to certified SDVOSB or VOSB offerors. Key contractor requirements include being an authorized distributor, acknowledging orders within 24 hours, and guaranteeing a minimum four-month expiration date on reagents. Additionally, the vendor must provide an emergency plan to deliver replacement supplies within 24 hours if products are found to be defective. Invoices must be submitted electronically, and payments will be processed in accordance with the Prompt Payment Act.
245-NETWORK Contract Office 5 (36C245)

POSTED

7 days ago

DEADLINE

in 7 days

AI Contract Overview

Show more

The contract outlined in the notice intends to award a sole source supply contract to Cerus Corporation for the provision of INTERCEPT Platelet Small Volume Processing Sets, INTERCEPT Platelet Processing Sets with Dual Storage Containers, and annual maintenance for specific Illuminator serial numbers in support of the Blood Bank Department at the Naval Hospital Guam. This action is based on the determination that only one source can meet the government's needs, as per the Federal Acquisition Regulation. The contract will be a firm fixed price agreement starting from December 1, 2024, with option years extending through November 30, 2027. Cerus Corporation is recognized for its expertise in pathogen reduction technology, having developed the FDA-approved INTERCEPT Blood System that enhances blood safety by significantly reducing the risks associated with transfusions. The company will be required to submit a capability statement, detailing their management and technical abilities, to demonstrate compliance with the contract specifications. Interested parties can challenge this sole source determination, but such challenges must be submitted by the specified deadline, and general inquiries will not be deemed substantive responses. Communication regarding this opportunity is directed strictly via email, emphasizing the importance of formal submissions.

General Info

Sole source contract awarded to Cerus Corporation for blood processing sets and maintenance.

Contract Value

$128,498

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

Agana Heights, GU, 96910, USA

Set-Aside

NONE

Award Issued Date

Documents

3

Naval Hospital Guam - Pathogen Reduction System SOW

PDF, High priority: read this firstsow
High

HT941025N0005 Notice of Intent to Sole Source

PDF, Low prioritypresolicitation
Low

JNCP - INTERCEPT Platelet Processing and Maintenance (NH Guam)

PDF, Low priorityjustification-and-authorization
Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseAwarded
Posted

Combined Synopsis

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → DEFENSE HEALTH AGENCY (DHA)
Contacts2 people available
OfficeFALLS CHURCH, VA, 22042, USA
Office AddressFALLS CHURCH, VA, 22042, USA
Contacts

Full Description

Show more

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Western Markets Contracting Division (WMCD), San Diego, intends to award a firm fixed price contract for INTERCEPT Platelet Small Volume Processing Set, INTERCEPT Platelet Processing Set with Dual Storage Containers, and Annual Maintenance for Illuminator Serial Numbers V02081701 and V0281702 in support of Blood Bank Department, Naval Hospital Guam in accordance with Federal Acquisition Regulation FAR 13.106-1(b)(1)(i), only one source being available to meet the Government’s needs, to:


Cerus Corporation


Unique Entity ID: KJJQRRLY2FL5
CAGE: 1PVJ6


1220 Concord Ave., Ste 600


Concord, CA 94520-4906



Period of Performance:


Base: 12/1/2024 – 11/30/2025


Option 1: 12/1/2025 – 11/30/2026


Option 2: 12/1/2026 – 11/30/2027



Cerus Corporation is a leading biotechnology company specializing in pathogen reduction technology for blood products. Their INTERCEPT Blood System is FDA approved for use with apheresis platelets and whole blood-derived plasma, significantly reducing the risk of transfusion-transmitted infections (TTIs) and sepsis. The system allows for the production of therapeutic platelet doses and plasma units, enhancing blood safety. Cerus Corporation holds exclusive licensing agreements and has a proven track record of providing highly specialized services that are critical for maintaining blood safety standards. Their unique qualifications make them the ideal choice for fulfilling the contract requirements.


This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required product for United States Naval Hospital Guam. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.


If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Merlinda M. Labaco at contact@example.gov. The closing date for challenges is no later than 1:00 pm Pacific Daylight Time, 4 November 2024.


NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED

More opportunities from Department Of Defense → DEFENSE HEALTH AGENCY (DHA)

Same awarding agency

NAICS: 561910
Federal
DHA - Offsite Sterile Processing Support Services
Solicitation # HT9427-27-RFI-0001
The Defense Health Agency (DHA) is conducting market research through a Request for Information (RFI) to identify qualified contractors capable of providing offsite sterile processing (SPD) support for various Military Treatment Facilities (MTFs). The primary goal is to enhance service resilience and workload stability by outsourcing the decontamination, assembly, and sterilization of surgical instruments, including minimally invasive surgical cases, power equipment, and Da Vinci accessories. The scope of work requires the contractor to manage the entire logistics chain, including providing transport containers and ensuring the secure, environmentally controlled transportation of contaminated instruments to offsite facilities and the return delivery of sterile inventory. This effort covers numerous MTFs across the United States, with specific critical locations designated as requiring no interruptions in service. Potential providers must adhere to rigorous industry and federal standards, including ANSI/AAMI ST79 and ST58, FDA 21 CFR Part 820, and various OSHA and DOT regulations. While the government has provided a general planning estimate of approximately 2,000 trays per month, final contract terms, award structures, and small business set-aside determinations will be decided based on the capabilities and feedback received from industry respondents. This is strictly a fact-finding mission and does not constitute a formal solicitation or an obligation to award a contract.
Packaging and Labeling Services

POSTED

7 days ago

DEADLINE

in 9 days
View Details
NAICS: 541715
Federal
DHA Enterprise-Wide Commercial Solutions Opening (CSO)
Solicitation # HT003826SC005
The Defense Health Agency (DHA) has established the Enterprise-Wide Commercial Solutions Opening (CSO), solicitation number HT003826SC005, to identify and acquire commercial products, services, and non-developmental items. Active from August 7, 2026, through August 6, 2027, this initiative seeks commercially available capabilities that can be deployed immediately or modified to meet DHA requirements across its Medical Digital Solutions, Medical Services, and Medical Products portfolios. The government will utilize a variety of award vehicles, including firm-fixed-price FAR-based contracts and Other Transaction (OT) agreements for research, prototyping, and experimental purposes under authorities such as 10 U.S.C. 3458, 3201, 4021, 4022, and 4023. The procurement process is driven by the issuance of specific Areas of Interest (AoI), which define problem statements, objectives, and submission criteria. Submissions undergo a streamlined, multi-phase evaluation process: Phase I involves a pitch or white paper evaluated on a Go/No-Go basis for strategic alignment and feasibility; Phase II may include an optional oral presentation or demonstration to assess technical viability; and Phase III requires a full commercial proposal evaluated on technical merit, cost reasonableness, and past performance. This CSO is administered by the DHACA Defense Healthcare Management Systems Contracting Division and is designed to prioritize cost-effective, commercially viable solutions to enhance healthcare readiness and patient safety.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

29 days ago

DEADLINE

N/A
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS